Investigating the effects of TCF4 mutations during oligodendrocyte development and maturation in a human-derived model of autism spectrum disorder

NIH RePORTER · NIH · F32 · $74,284 · view on reporter.nih.gov ↗

Abstract

Project Summary/Abstract Pitt-Hopkins Syndrome (PTHS) is a rare form of autism spectrum disorder (ASD) characterized by developmental delay, breathing abnormalities, seizure, lack of speech, and abnormal facies. PTHS is caused by de novo mutations in Transcription Factor 4 (TCF4), a key transcription factor that orchestrates multiple neurodevelopmental programs. Previous studies from our laboratory using PTHS mouse models showed dysregulation in the density of oligodendrocyte progenitor cells (OPCs) and maturity of functional oligodendrocytes (OLs), which resulted in myelination deficits. However, these deficiencies have not been studied in the human system. The current proposal centers on exploring the effects of TCF4 mutations in human OLs generated from patient-derived induced pluripotent stem cells (iPSCs). Our laboratory has generated a collection of iPSCs that harbor various disease-causing mutations in TCF4 that result in the expression of putative dominant-negative proteins or haploinsufficiency. To determine if patient-specific mutations in TCF4 result in dysregulation of the OL lineage, we differentiated iPSC using a two-dimensional and a three-dimensional OL generating protocol. The goals for this proposal focus on (1) characterizing the effects of mutations in TCF4 during oligodendrogenesis and OL maturation in a patient-derived iPSC model, (2) identifying TCF4’s interactome during OL specification, and (3) generating a platform for pro-myelinating drug screening. The proposed approach is innovative and significant, as it aims to shed light on the process of myelination and the genetic regulators that guide OL maturation and survival. Moreover, this proposal will allow for the develop of 2-D and 3-D human-derived platforms with the capacity to rapidly screen promising pro-myelinating drugs that could improve patient quality of life. This fellowship will help the applicant develop the expertise necessary to conduct basic biological, functional and translational research as an independent investigator in the area of neuropsychiatric and neurodevelopmental diseases.

Key facts

NIH application ID
10996523
Project number
1F32MH135665-01A1
Recipient
LIEBER INSTITUTE, INC.
Principal Investigator
Alejandra Ines Romero Morales
Activity code
F32
Funding institute
NIH
Fiscal year
2024
Award amount
$74,284
Award type
1
Project period
2024-12-12 → 2027-12-11